Sensei Biotherapeutics (SNSE)

Sensei Biotherapeutics Stock Analysis & Ratings

SNSE Stock Chart & Stats

Day’s Range$1.62 - $1.74
52-Week Range$1.45 - $15.12
Previous Close$1.6
Average Volume (3M)79.31K
Market Cap$52.07M
P/E Ratio-1.4
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)-1.20



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Sensei Biotherapeutics’s price range in the past 12 months?
Sensei Biotherapeutics lowest stock price was $1.45 and its highest was $15.12 in the past 12 months.
    What is Sensei Biotherapeutics’s market cap?
    Sensei Biotherapeutics’s market cap is $52.07M.
      What is Sensei Biotherapeutics’s price target?
      The average price target for Sensei Biotherapeutics is $5.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $6.00 ,the lowest forecast is $4.00. The average price target represents 194.12% Increase from the current price of $1.7.
        What do analysts say about Sensei Biotherapeutics?
        Sensei Biotherapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Sensei Biotherapeutics’s upcoming earnings report date?
          Sensei Biotherapeutics’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
            How were Sensei Biotherapeutics’s earnings last quarter?
            Sensei Biotherapeutics released its earnings results on May 10, 2022. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.05.
              Is Sensei Biotherapeutics overvalued?
              According to Wall Street analysts Sensei Biotherapeutics’s price is currently Undervalued.
                Does Sensei Biotherapeutics pay dividends?
                Sensei Biotherapeutics does not currently pay dividends.
                What is Sensei Biotherapeutics’s EPS estimate?
                Sensei Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Sensei Biotherapeutics have?
                Sensei Biotherapeutics has 30,630,000 shares outstanding.
                  What happened to Sensei Biotherapeutics’s price movement after its last earnings report?
                  Sensei Biotherapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went up 9.804%.
                    Which hedge fund is a major shareholder of Sensei Biotherapeutics?
                    Among the largest hedge funds holding Sensei Biotherapeutics’s share is Moore Capital Management LP. It holds Sensei Biotherapeutics’s shares valued at N/A.


                      Sensei Biotherapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(194.12% Upside)
                      Moderate Buy
                      The Sensei Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Sensei Biotherapeutics

                      Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The companies ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis